NIH Reluctant To “March In”: Collins Suggests Authority Not Intended To Address Pricing Concerns
This article was originally published in RPM Report
Executive Summary
Legislators are urging the National Institutes of Health to use intellectual property levers to put pressure on prescription drug pricing. NIH has historically been reluctant to play the role of the price police – and it still is.
You may also be interested in...
‘March In’ Plan Unveiled By Democratic Think Tank: A Battle Biopharma Would Welcome?
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.
Pricing In ‘Exceptional’ Times: ICER Aims To Shape US Policy For Novel COVID Drugs, Vaccines
US Institute for Clinical and Economic Review lays out options ranging from the status quo (unrestricted pricing) to compulsory licensing and advanced market commitments in a new white paper.
Pricing In ‘Exceptional’ Times: ICER Aims To Shape US Policy For Novel COVID Drugs, Vaccines
US Institute for Clinical and Economic Review lays out options ranging from the status quo (unrestricted pricing) to compulsory licensing and advanced market commitments in a new white paper.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: